CurrentBlue Cross Blue Shield - OklahomaPolicy N/A

Prior Authorization Programs for Members on the Basic Drug List or Enhanced Drug List

Lists prescription drug categories and specific medications that are subject to prior authorization for members on the payer's Basic Drug List or Enhanced Drug List. Affects providers prescribing or dispensing the listed drugs for Blue Cross Blue Shield - Oklahoma members.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyPrior Authorization Programs for Members on the Basic Drug List or Enhanced Drug List

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization before dispensing any medication listed on the Basic or Enhanced Drug List.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20+document chunks processed

multipledrug categories listed

manyindividual drug entries

manybrand-to-category mappings

phone referencedmember contact guidance

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria Overview

This document functions as a payer-maintained drug list requiring prior authorization rather than a detailed medical necessity policy. It identifies prescription drug categories and specific brand and generic agents that are subject to prior authorization for members on the plan's Basic Drug List or Enhanced Drug List. Providers must obtain prior authorization before dispensing agents listed in these categories.

These prior authorization programs are subject to change and the payer may add additional drugs to the categories shown. The fragment does not list explicit exclusions; absence of a drug or category here should not be interpreted as an affirmation of coverage or exclusion without consulting the current payer lists.

Provider Actions & Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for drugs and brand-name agents listed on the Basic Drug List or Enhanced Drug List. Providers must obtain authorization before dispensing or submitting claims for these agents to avoid denial of coverage.

Applies to all prescription drugs and named brands appearing in the Basic/Enhanced Drug List sections (examples include: Afrezza, Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, Reyvow, Trudhesa, and many others listed under the Basic/Enhanced Drug List).

Documentation Required

Required Documentation

Use of any listed drug requires a documented prescription and supporting clinical information when submitting the prior authorization request. Include diagnosis, prior therapies tried (if applicable), dosing, and relevant medical records to demonstrate medical necessity.

Documented prescription for the specific listed agent is required at time of PA submission.
Include prior treatment history and clinical rationale when step therapy or therapeutic alternatives are relevant.

Step Therapy

Implied Step Therapy / Preferred Alternatives

If a listed drug is used when a preferred therapeutic alternative exists, step therapy or substitution with the preferred product may be required. The policy groups many agents into therapeutic or supplemental alternative groupings — prescribing a non-preferred brand may trigger a requirement to try the preferred alternative first.

Examples of implied step/alternative mappings from the list: Methitest/Vogelxo mapping implies preferred alternatives for testosterone formulations; CGRP agents list shows multiple branded options where specific preferred CGRP products may be designated.
Providers should review the therapeutic alternatives and consider step therapy before requesting PA.

Step Therapy

Alternatives / Step Implications

Therapeutic alternatives and supplemental groupings are identified within the drug list; when an alternative-preferred agent is available, prior authorization may require failure or intolerance of the preferred product before coverage of the non-preferred agent is approved.

The policy lists several "Therapeutic Alternatives" and "Supplemental Therapeutic Alternatives" groupings (for example, Therapeutic Alternatives entries in the list).
When a supplemental preferred agent exists, PA reviewers may request documentation of trial and failure/intolerance of that agent.

Denial Risk

Denial Risk if PA Not Obtained

Failure to obtain prior authorization for drugs subject to PA may result in claim denial or member liability. Providers should secure authorization before dispensing or billing for listed agents.

Denial risk applies to all drugs identified under the Basic Drug List or Enhanced Drug List if PA is not obtained.
Obtain PA to prevent claim denial and potential member balance billing.

Note

Contact for PA Questions

For questions about the prior authorization process or specific PA requirements for a member, contact the number shown on the member's ID card.

Call the phone number on the member ID card for PA questions and instructions.

Key Definitions

Basic Drug List / Enhanced Drug List

DefinitionPlan-specific formulary tiers called the 'Basic Drug List' and 'Enhanced Drug List' that determine which prescription drugs and drug categories require prior authorization for members.

ScopeApplies to prescription drugs and drug categories listed in this document (e.g., actinic keratosis topicals, acute migraine agents, alternative dosage forms, inhaled/insulin/other specialty agents).

Provider obligationDrugs and drug categories shown are subject to prior authorization for members on the Basic Drug List or Enhanced Drug List; providers must obtain authorization before dispensing these medications.

DocumentationA documented prescription for a listed drug should be provided when submitting a prior authorization request.

UpdatesThe lists and program may be updated with additional drugs over time; providers should check the current payer resources for changes.

Step Therapy / Preferred Agents

Preferred agent	Mapped (alternative) agent	Coverage requirement
Methitest
Vogelxo

Therapeutic group / note	Example preferred alternatives (grouped)	Coverage implication
Therapeutic Alternatives (general)
Absorica; Kitabis Pak; Absorica LD; Konvomep suspension; Adapalene; Lexette

Background

The list maps formulary categories to specific branded and generic agents, grouping therapies by indication (for example, topical agents for actinic keratosis, acute migraine therapies, inhaled products and many specialty agents). Where categories are shown, specific product names (brand and generic) are provided so prescribers and dispensing pharmacies can determine which prescriptions require prior authorization under the plan's Basic Drug List or Enhanced Drug List.